Rachel Bluebond

Rachel Bluebond

Auto-generated profile, based on publicly available information

Rachel Bluebond

GC (Genetic Counsellor), Clinical Cancer Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
NENisreen Elsayegh
Nisreen Elsayegh
RWRachel D. Webster
Rachel D. Webster
AGAngelica Gutierrez
Angelica Gutierrez
HLHeather Lin
Heather Lin
HKHenry M. Kuerer
Henry M. Kuerer
BABanu K. Arun
Banu K. Arun
Although multigene panel testing is increasingly common in patients with cancer, the relationship between its use among breast cancer patients with non‐BRCA mutations or variants of uncertain significance (VUS) and disease management decisions has not been well described. This study evaluated the rate and predictive factors of CPM patients who underwent multigene panel testing. Three hundred and fourteen patients with breast cancer who underwent multigene panel testing between 2014 and 2017 were included in the analysis. Of the 314 patients, 70 elected CPM. Election of CPM by gene status was as follows: BRCA carriers (42.3%), non‐BRCA carriers (30.1%), and VUS (10.6%). CPM election rates did not differ between non‐BRCA carriers and BRCA carriers (P = 0.6205). Among non‐BRCA carriers, negative hormone receptor status was associated with CPM (P = 0.0115). For those with a VUS, hormone receptor status was not associated with CPM (P = 0.1879). Although the rate of CPM between BRCA carriers and non‐BRCA carriers was not significantly different, the predictors of CPM were different in each group. Our analyses shed the light on the increasing use of CPM among patients who are non‐BRCA carriers as well those with a VUS. Our study elucidates the differing predictive factors of CPM election among BRCA carriers, non‐BRCA carries, and those with a VUS. Our findings reveal the need for providers to be cognizant that non‐BRCA genes and VUS drive women to elect CPM despite the lack of data for contralateral breast cancer risk associated with these genes.

23 August 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
BABanu K. Arun
Banu K. Arun
SPSusan K. Peterson
Susan K. Peterson
LSLilian E. Sweeney
Lilian E. Sweeney
RBRachel D. Bluebond
Rachel D. Bluebond
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
AKAnne C. Kushwaha
Anne C. Kushwaha

17 October 2017 in Cancer
Verified
Journal Article
Open access
PDF file
AGAngelica Gutierrez
Angelica Gutierrez
TFTamer M. Fouad
Tamer M. Fouad
JSJuhee Song
Juhee Song
RWRachel Webster
Rachel Webster
NENisreen Elsayegh
Nisreen Elsayegh
BABanu K. Arun
Banu K. Arun
BACKGROUND: Inflammatory breast cancer (IBC) often affects women at a relatively young age. To the authors' knowledge, the rate of BRCA variants among patients with IBC is not known. To determine the association between BRCA status and IBC, the authors evaluated its rate and compared the clinicopathologic characteristics of patients with IBC with those of patients with other breast cancers (non‐IBC).METHODS: Patients who presented at the study institution's cancer genetics program and who underwent BRCA genetic testing were included in the current study. The authors compared clinicopathologic data between patients with IBC and those with non‐IBC using propensity score matching to identify predictors.RESULTS: A total of 1789 patients who underwent BRCA genetic testing (1684 with non‐IBC and 105 with IBC) were included. BRCA pathogenic variants were found in 27.3% of patients with non‐IBC and 18.1% of patients with IBC (P = .0384). After propensity score matching, there were no significant differences noted between patients with IBC and those with non‐IBC, including the rate of BRCA pathogenic variants (P = .5485). However, a subgroup analysis of the 479 patients with BRCA pathogenic variants demonstrated that patients with IBC (19 patients) were diagnosed at significantly younger ages compared with patients with non‐IBC (P = .0244).CONCLUSIONS: There was no clear association observed between BRCA pathogenic variants and IBC. However, among patients who tested positive for BRCA pathogenic variants, those with IBC were younger at the time of diagnosis compared with those with non‐IBC breast cancers. These results confirm that genetic testing is important for patients with IBC who meet the current clinical criteria for genetic testing in breast cancer. Cancer 2018;124:466‐74. © 2017 American Cancer Society.

19 December 2017 in Cancer
Verified
Journal Article
Open access
PDF file
RWRachel D. Webster
Rachel D. Webster
JRJessica L. Ross
Jessica L. Ross
BABanu K. Arun
Banu K. Arun
With the expansion of hereditary cancer panel testing, it is vital to fully evaluate the benefits and limitations of each testing option to ensure proper patient care and prudent use of health care resources. Continuous education for health care providers is necessary for continued integration of genetic testing into oncology care.

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DKDarya Aleksandrovna Kizub
Darya Aleksandrovna Kizub
RBRachel Bluebond
Rachel Bluebond
SGSierra Green
Sierra Green
JDJessica Duckworth
Jessica Duckworth
SSSreejesh Shanker
Sreejesh Shanker
BABanu Arun
Banu Arun
6548 Background: Hereditary breast cancer accounts for 5-10% of all cases, but only 20% of eligible women undergo NCCN guideline-concordant screening. We demonstrated previously that our simple genetic risk screening tool (GRST) and telegenetics improved adherence to genetic testing guidelines and increased high-risk cancer surveillance. Our objective was to identify women eligible for genetic testing using breast cancer screening clinics in underserved communities as entry points, reach them with our tailored program, and measure impact. Methods: This is a prospective study in women presenting for breast cancer screening at The Rose, which provides breast imaging to underserved patients in Houston, TX. Women who consented to participate filled out the GRST and provided socio-demographic information. Those at high risk for hereditary cancer after GRST scoring were provided with educational materials and sent a saliva-based genetic testing kit. When results included a pathogenic variant (PV) or variant of uncertain significance (VUS), individuals received telegenetic counseling and risk reduction resources. Others were notified of negative results by phone. The program included education for providers about importance of genetic testing. Socio-demographic characteristics were analyzed using descriptive statistics. All statistical tests were two-sided. Results: 501 women filled out the GRST. Median age was 52. Median annual salary was $45,000 (IQR 21-75K). 151 (36.3%) were uninsured. 252 (50.3%) identified as White, 230 (45.9%) as Hispanic/Latino, and 106 (21.2%) as Black/African American. 150 (33%) were eligible for genetic testing; 100 could be contacted. Of the 100, 41 declined testing, 40 were lost to follow-up, 19 agreed, and 15 (10% of those eligible) returned the kits. Results included 11 negative, 2 VUS, 1 PV (NF1). Among 41 who declined testing, reported reasons included not wanting to know the results or preference to follow-up with their primary care doctor in 11 (26.8%) each, not enough time or prior genetic testing in 6 (14.6%) each, no reason given by five, and perception that testing was unnecessary in two. Completion of genetic testing was not associated with insurance, salary, family history, or race/ethnicity (p > 0. 05). Conclusions: Our study was successful in identifying underserved women at high risk of hereditary cancer who have not previously undergone genetic testing using a simple screening tool. We reduced barriers to genetic testing by working with a trusted community organization and using remote testing and telegenetics. We did not find any factors associated with genetic testing completion, though results are limited by small sample size. Given the low proportion of patients who completed testing, the next project phase will focus on improving convenience for patients and exploring patient and program-related reasons for non-completion of testing and strategies to overcome these.

21 October 2022
Verified
Book Chapter
Closed access
RBRachel Bluebond
Rachel Bluebond
SBSarah A. Bannon
Sarah A. Bannon
SHSamuel M. Hyde
Samuel M. Hyde
AWAshley H. Woodson
Ashley H. Woodson
NYNancy Y.‐Q. You
Nancy Y.‐Q. You
BABanu K. Arun
Banu K. Arun